Table 5 Performance of the ADNEX model with vs. without CA 125 level in discriminating stage I OC vs. stage II–IV OC and stage II–IV OC vs. metastasis
ADNEX model | AUC (95% CI) | Sensitivity (95% CI) (%) | Specificity (95% CI) (%) | PPV (95% CI) (%) | NPV (95% CI) (%) | LR+ (95% CI) | LR- (95% CI) | DOR | aOptimal cut-off (%) | P |
|---|---|---|---|---|---|---|---|---|---|---|
Benign vs. Stage II–IV OC | ||||||||||
With CA 125 | 0.99 (0.99–1.00) | 100.00 (100.00–100.00) | 98.97 (97.44–100.00) | 92.73 (83.61–100.00) | 100.00 (100.00–100.00) | 97.09 (43.80–215.22) | 0.00 (−) | 0.00 | 42.95 | 0.03 |
Without CA 125 | 0.99 (0.99–1.00) | 100.00 (100.00–100.00) | 97.69 (96.15–99.23) | 85.00 (77.27–94.44) | 100.00 (100.00–100.00) | 43.29 (22.70–82.57) | 0.00 (−) | 0.00 | 40.75 | |
Stage I OC vs. Stage II–IV OC | ||||||||||
With CA 125 | 0.88 (0.80–0.96) | 80.39 (68.63–90.20) | 98.53 (95.59–100.00) | 97.67 (92.68–100.00) | 87.01 (80.95–93.15) | 54.69 (7.78–384.48) | 0.20 (0.11–0.35) | 273.45 | 36.2 | 0.01 |
Without CA 125 | 0.94 (0.88–0.99) | 84.31 (72.55–94.12) | 98.53 (95.59–100.00) | 97.78 (93.18–100.00) | 89.33 (82.93–95.65) | 57.35 (8.17–402.77) | 0.16 (0.08–0.30) | 358.44 | 30.55 | |
Stage II–IV OC vs. metastasis | ||||||||||
With CA 125 | 0.86 (0.76–0.95) | 100.00 (100.00–100.00) | 84.31 (72.55–92.16) | 33.33 (22.22–50.00) | 100.00 (100.00–100.00) | 6.37 (3.50–11.61) | 0.00 (−) | – | 31.25 | 0.01 |
Without CA 125 | 0.97 (0.93–1.00) | 100.00 (100.00–100.00) | 96.08 (90.20–100.00) | 66.67 (44.44–100.00) | 100.00 (100.00–100.00) | 25.51 (6.56–99.24) | 0.00 (−) | – | 15.2 | |